Cytek Biosciences (CTKB) Stock Forecast, Price Target & Predictions
CTKB Stock Forecast
Cytek Biosciences stock forecast is as follows: an average price target of $8.50 (represents a 73.12% upside from CTKB’s last price of $4.91) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CTKB Price Target
The average price target for Cytek Biosciences (CTKB) is $8.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $8.50 to $8.50. This represents a potential 73.12% upside from CTKB's last price of $4.91.
CTKB Analyst Ratings
According to 4 Wall Street analysts, Cytek Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CTKB stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cytek Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 13, 2024 | Dave Westenberg | Piper Sandler | $8.50 | $6.15 | 38.21% | 73.12% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $16.00 | $14.08 | 13.64% | 225.87% |
| May 15, 2022 | David Westenberg | Piper Sandler | $12.00 | $9.38 | 27.93% | 144.40% |
The latest Cytek Biosciences stock forecast, released on May 13, 2024 by Dave Westenberg from Piper Sandler, set a price target of $8.50, which represents a 38.21% increase from the stock price at the time of the forecast ($6.15), and a 73.12% increase from CTKB last price ($4.91).
Cytek Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $8.50 |
| Last Closing Price | $4.91 | $4.91 | $4.91 |
| Upside/Downside | -100.00% | -100.00% | 73.12% |
In the current month, the average price target of Cytek Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cytek Biosciences's last price of $4.91. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 13, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 14, 2023 | Stephens | - | Positive | Initialise |
| Oct 24, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 19, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 15, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 12, 2022 | Goldman Sachs | Buy | Buy | Hold |
Cytek Biosciences's last stock rating was published by Piper Sandler on May 13, 2024. The company gave CTKB a "Overweight" rating, the same as its previous rate.
Cytek Biosciences Financial Forecast
Cytek Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $58.60M | $48.00M | $49.69M | $37.09M | $48.34M | $40.48M | - | $35.06M | $38.89M | $34.38M | $30.41M |
| Avg Forecast | $81.22M | $66.80M | $63.39M | $56.99M | $70.58M | $59.36M | $54.93M | $49.67M | $60.30M | $51.84M | $49.53M | $43.59M | $56.58M | $55.48M | $45.71M | $47.15M | $50.22M | $43.29M | $39.63M | $32.51M | $36.42M | $33.37M | $28.27M |
| High Forecast | $84.76M | $69.71M | $66.15M | $59.48M | $73.65M | $61.95M | $57.32M | $51.84M | $62.93M | $53.41M | $51.69M | $45.49M | $59.05M | $57.89M | $47.71M | $49.20M | $52.41M | $45.18M | $39.63M | $34.47M | $38.62M | $35.39M | $29.98M |
| Low Forecast | $77.27M | $63.55M | $60.31M | $54.22M | $67.15M | $56.47M | $52.26M | $47.26M | $57.37M | $49.30M | $47.12M | $41.47M | $53.83M | $52.78M | $43.49M | $44.85M | $47.78M | $41.18M | $39.63M | $30.92M | $34.64M | $31.74M | $26.89M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.87% | 1.09% | 0.79% | 0.96% | 0.94% | - | 1.08% | 1.07% | 1.03% | 1.08% |
Cytek Biosciences's average Quarter revenue forecast for Mar 24 based on 1 analysts is $43.59M, with a low forecast of $41.47M, and a high forecast of $45.49M. CTKB's average Quarter revenue forecast represents a -25.62% decrease compared to the company's last Quarter revenue of $58.60M (Dec 23).
Cytek Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $3.32M | $-3.59M | $-9.13M | $-8.37M | $4.80M | $3.27M | - | $-1.24M | $936.00K | $2.71M | $3.90M |
| Avg Forecast | $3.74M | $3.07M | $2.92M | $2.62M | $3.25M | $2.73M | $2.53M | $2.28M | $2.77M | $2.38M | $2.28M | $2.01M | $2.60M | $2.55M | $2.10M | $2.17M | $2.31M | $1.99M | $1.82M | $1.50M | $1.68M | $1.54M | $1.30M |
| High Forecast | $3.90M | $3.21M | $3.04M | $2.74M | $3.39M | $2.85M | $2.64M | $2.38M | $2.89M | $2.46M | $2.38M | $2.09M | $2.72M | $2.66M | $2.19M | $2.26M | $2.41M | $2.08M | $1.82M | $1.59M | $1.78M | $1.63M | $1.38M |
| Low Forecast | $3.55M | $2.92M | $2.77M | $2.49M | $3.09M | $2.60M | $2.40M | $2.17M | $2.64M | $2.27M | $2.17M | $1.91M | $2.48M | $2.43M | $2.00M | $2.06M | $2.20M | $1.89M | $1.82M | $1.42M | $1.59M | $1.46M | $1.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.28% | -1.41% | -4.34% | -3.86% | 2.08% | 1.64% | - | -0.83% | 0.56% | 1.76% | 3.00% |
1 analysts predict CTKB's average Quarter EBITDA for Mar 24 to be $2.01M, with a high of $2.09M and a low of $1.91M. This is -39.66% lower than Cytek Biosciences's previous annual EBITDA (Dec 23) of $3.32M.
Cytek Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $6.30M | $-6.46M | $-4.39M | $-6.81M | $3.53M | $1.67M | - | $-2.16M | $-1.17M | $1.42M | $2.67M |
| Avg Forecast | $12.57M | $4.59M | $2.22M | $19.72K | $11.80M | $5.51M | $2.33M | $-254.99K | $8.99M | $2.61M | $-376.84K | $-3.29M | $3.94M | $2.89M | $1.58M | $2.96M | $5.59M | $1.64M | $1.64M | $-1.31M | $3.27M | $3.05M | $1.31M |
| High Forecast | $13.28M | $4.85M | $2.35M | $20.83K | $12.47M | $5.82M | $2.46M | $-238.88K | $9.50M | $7.83M | $-353.02K | $-3.08M | $4.17M | $3.06M | $1.67M | $3.13M | $5.90M | $1.74M | $1.64M | $-1.22M | $3.52M | $3.29M | $1.41M |
| Low Forecast | $11.77M | $4.30M | $2.08M | $18.47K | $11.05M | $5.16M | $2.18M | $-269.45K | $8.43M | $-2.61M | $-398.20K | $-3.47M | $2.63M | $2.71M | $1.48M | $2.77M | $5.23M | $1.54M | $1.64M | $-1.41M | $3.06M | $2.86M | $1.22M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.60% | -2.23% | -2.78% | -2.30% | 0.63% | 1.01% | - | 1.65% | -0.36% | 0.47% | 2.04% |
Cytek Biosciences's average Quarter net income forecast for Mar 24 is $-3.29M, with a range of $-3.47M to $-3.08M. CTKB's average Quarter net income forecast represents a -152.16% decrease compared to the company's last Quarter net income of $6.30M (Dec 23).
Cytek Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $21.90M | $22.43M | $25.15M | $23.23M | $19.54M | $16.85M | - | $14.51M | $15.24M | $12.30M | $9.74M |
| Avg Forecast | $29.24M | $24.05M | $22.82M | $20.52M | $25.41M | $21.37M | $19.78M | $17.88M | $21.71M | $18.67M | $17.83M | $15.69M | $20.37M | $19.97M | $16.46M | $16.98M | $18.08M | $15.59M | $14.27M | $11.71M | $13.11M | $12.02M | $10.18M |
| High Forecast | $30.52M | $25.10M | $23.82M | $21.42M | $26.52M | $22.31M | $20.64M | $18.66M | $22.66M | $19.23M | $18.61M | $16.38M | $21.26M | $20.85M | $17.18M | $17.72M | $18.87M | $16.27M | $14.27M | $12.41M | $13.91M | $12.74M | $10.79M |
| Low Forecast | $27.82M | $22.88M | $21.72M | $19.52M | $24.18M | $20.33M | $18.82M | $17.02M | $20.66M | $17.75M | $16.97M | $14.93M | $19.38M | $19.00M | $15.66M | $16.15M | $17.20M | $14.83M | $14.27M | $11.13M | $12.47M | $11.43M | $9.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 1.12% | 1.53% | 1.37% | 1.08% | 1.08% | - | 1.24% | 1.16% | 1.02% | 0.96% |
Cytek Biosciences's average Quarter SG&A projection for Mar 24 is $15.69M, based on 1 Wall Street analysts, with a range of $14.93M to $16.38M. The forecast indicates a -28.34% fall compared to CTKB last annual SG&A of $21.90M (Dec 23).
Cytek Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | - | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.05 | $-0.05 | $-0.03 | $-0.05 | $0.03 | $0.01 | - | $-0.02 | $-0.01 | - | $0.02 |
| Avg Forecast | $0.10 | $0.03 | $0.02 | - | $0.09 | $0.04 | $0.02 | $-0.00 | $0.07 | $0.02 | $-0.00 | $-0.03 | $0.03 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.02 | $0.01 |
| High Forecast | $0.10 | $0.04 | $0.02 | - | $0.09 | $0.04 | $0.02 | $-0.00 | $0.07 | $0.06 | $-0.00 | $-0.02 | $0.03 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.03 | $0.03 | $0.01 |
| Low Forecast | $0.09 | $0.03 | $0.02 | - | $0.08 | $0.04 | $0.02 | $-0.00 | $0.06 | $-0.02 | $-0.00 | $-0.03 | $0.02 | $0.02 | $0.01 | $0.02 | $0.04 | $0.01 | $0.01 | $-0.01 | $0.02 | $0.02 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.61% | -2.15% | -2.69% | -2.23% | 0.61% | 0.80% | - | 1.61% | -0.43% | 0.19% | 2.04% |
According to 1 Wall Street analysts, Cytek Biosciences's projected average Quarter EPS for Mar 24 is $-0.03, with a low estimate of $-0.03 and a high estimate of $-0.02. This represents a -151.87% decrease compared to CTKB previous annual EPS of $0.05 (Dec 23).
Cytek Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VAPO | Vapotherm | $2.16 | $128.00 | 5825.93% | Hold |
| APYX | Apyx Medical | $1.16 | $8.50 | 632.76% | Buy |
| INGN | Inogen | $11.33 | $26.00 | 129.48% | Buy |
| OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
| NPCE | NeuroPace | $7.43 | $12.88 | 73.35% | Buy |
| CTKB | Cytek Biosciences | $4.91 | $8.50 | 73.12% | Buy |
| SGHT | Sight Sciences | $6.95 | $10.33 | 48.63% | Hold |
| LUNG | Pulmonx | $8.31 | $12.25 | 47.41% | Buy |
| LIVN | LivaNova | $48.53 | $71.25 | 46.82% | Buy |
| KIDS | OrthoPediatrics | $32.28 | $40.80 | 26.39% | Buy |
| RXST | RxSight | $54.96 | $68.60 | 24.82% | Buy |
| SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
CTKB Forecast FAQ
Is Cytek Biosciences a good buy?
Yes, according to 4 Wall Street analysts, Cytek Biosciences (CTKB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 75.00% of CTKB's total ratings.
What is CTKB's price target?
Cytek Biosciences (CTKB) average price target is $8.5 with a range of $8.5 to $8.5, implying a 73.12% from its last price of $4.91. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cytek Biosciences stock go up soon?
According to Wall Street analysts' prediction for CTKB stock, the company can go up by 73.12% (from the last price of $4.91 to the average price target of $8.5), up by 73.12% based on the highest stock price target, and up by 73.12% based on the lowest stock price target.
Can Cytek Biosciences stock reach $7?
CTKB's average twelve months analyst stock price target of $8.5 supports the claim that Cytek Biosciences can reach $7 in the near future.
What are Cytek Biosciences's analysts' financial forecasts?
Cytek Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $234.54M (high $244.76M, low $223.13M), average EBITDA is $10.79M (high $11.26M, low $10.26M), average net income is $19.38M (high $20.51M, low $18.13M), average SG&A $84.45M (high $88.13M, low $80.34M), and average EPS is $0.147 (high $0.156, low $0.138). CTKB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $268.4M (high $280.1M, low $255.36M), average EBITDA is $12.35M (high $12.89M, low $11.75M), average net income is $19.39M (high $20.49M, low $18.17M), average SG&A $96.64M (high $100.86M, low $91.94M), and average EPS is $0.148 (high $0.156, low $0.138).
Did the CTKB's actual financial results beat the analysts' financial forecasts?
Based on Cytek Biosciences's last annual report (Dec 2023), the company's revenue was $193.39M, which missed the average analysts forecast of $204.92M by -5.63%. Apple's EBITDA was $-17.546M, missing the average prediction of $9.43M by -286.13%. The company's net income was $-11.329M, missing the average estimation of $11.37M by -199.64%. Apple's SG&A was $92.69M, beating the average forecast of $73.78M by 25.63%. Lastly, the company's EPS was $-0.0867, missing the average prediction of $0.0865 by -200.23%. In terms of the last quarterly report (Dec 2023), Cytek Biosciences's revenue was $58.6M, beating the average analysts' forecast of $56.58M by 3.57%. The company's EBITDA was $3.32M, beating the average prediction of $2.6M by 27.66%. Cytek Biosciences's net income was $6.3M, beating the average estimation of $3.94M by 59.77%. The company's SG&A was $21.9M, beating the average forecast of $20.37M by 7.49%. Lastly, the company's EPS was $0.0482, beating the average prediction of $0.03 by 60.67%